Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to -$68702.0.

  • China Pharma Holdings' Change in Accured Expenses fell 2163.52% to -$68702.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $762943.0, marking a year-over-year increase of 52043.02%. This contributed to the annual value of $432051.0 for FY2024, which is 6760.58% up from last year.
  • Per China Pharma Holdings' latest filing, its Change in Accured Expenses stood at -$68702.0 for Q3 2025, which was down 2163.52% from $187274.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Change in Accured Expenses ranged from a high of $804339.0 in Q4 2022 and a low of -$450887.0 during Q1 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $60704.0 (2021), whereas its average is $96331.8.
  • In the last 5 years, China Pharma Holdings' Change in Accured Expenses surged by 156375.02% in 2021 and then crashed by 57919.91% in 2022.
  • Quarter analysis of 5 years shows China Pharma Holdings' Change in Accured Expenses stood at $207099.0 in 2021, then soared by 288.38% to $804339.0 in 2022, then plummeted by 47.67% to $420886.0 in 2023, then surged by 73.44% to $729967.0 in 2024, then plummeted by 109.41% to -$68702.0 in 2025.
  • Its Change in Accured Expenses was -$68702.0 in Q3 2025, compared to $187274.0 in Q2 2025 and -$85596.0 in Q1 2025.